Long-Term Follow-up Study of Women With Early Stage Invasive Breast Cancer Previously in GEICAM Clinical Trials

What this Trial Is About

Researchers are conducting a long-term observational study to collect information from patients diagnosed with early-stage invasive breast cancer. These patients were previously part of neoadjuvant or adjuvant clinical trials conducted by the GEICAM group, starting from 1998. The study aims to evaluate the long-term effects and outcomes of breast cancer treatments over an extended follow-up period. The study includes patients who completed follow-up in the original GEICAM trials and will continue to monitor them for approximately 30 years. This extended observation allows researchers to assess long-term event-free survival and disease-free survival, along with overall survival, providing valuable insights into the durability of treatment effects and potential late effects. Participants will be followed regularly during this period, with data collected to track their health status and cancer outcomes. The study gathers vital information useful for healthcare professionals, hospital managers, patients, and society to better understand long-term needs and treatment impacts in early-stage invasive breast cancer. The total participation duration can be up to 30 years from the start of the study.

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies